Protein kinase Cs (PKCs) constitute a family of serine/threonine kinases, which has distinguished and specific roles in regulating cardiac responses, including those associated with heart failure. We found that the PKCh isoform is expressed at considerable levels in the cardiac muscle in mouse, and that it is rapidly activated after pressure overload. To investigate the role of PKCh in cardiac remodeling, we used PKCh À/À mice. In vivo analyses of PKCh À/À hearts showed that the lack of PKCh expression leads to left ventricular dilation and reduced function. Histological analyses showed a reduction in the number of cardiomyocytes, combined with hypertrophy of the remaining cardiomyocytes, cardiac fibrosis, myofibroblast hyper-proliferation and matrix deposition. We also observed p38 and JunK activation, known to promote cell death in response to stress, combined with upregulation of the fetal pattern of gene expression, considered to be a feature of the hemodynamically or metabolically stressed heart. In keeping with these observations, cultured PKCh À/À cardiomyocytes were less viable than wild-type cardiomyocytes, and, unlike wild-type cardiomyocytes, underwent programmed cell death upon stimulation with a1-adrenergic agonists and hypoxia. Taken together, these results show that PKCh maintains the correct structure and function of the heart by preventing cardiomyocyte cell death in response to work demand and to neuro-hormonal signals, to which heart cells are continuously exposed.
The heart responds to different pathological stimuli, which make it function harder under conditions of hemodynamic overload, by inducing an increase in muscle mass, triggering left ventricular (LV) hypertrophy. 1 This remodeling is considered a compensatory response to the altered workload, allowing the heart to function harder under conditions of sustained stress. However, LV hypertrophy is clinically associated with a significant increase in the risk of heart failure, dilated cardiomyopathy, ischemic heart disease and sudden death, leading to increased cardiovascular mortality. Actually, LV hypertrophy is often followed by LV dilation, which is a reduction in muscle mass, an increase in fibrotic tissue and an enlargement in cavity diameter. This further remodeling results in functional alterations and eventually in the development of heart failure. 1 Many studies have suggested that members of the protein kinase C (PKC) family have a role in cardiac structure. Early studies have shown that TPA, a known PKC activator, activates the fetal gene program and increases cardiomyocyte size. 2, 3 However, as the family of serine/threonine protein kinases C comprises at least 12 isoforms, those early studies were somewhat unspecific. Later studies, in fact, showed that many of the PKC isoforms are expressed at appreciable levels in the myocardium and selectively regulate a number of cardiac responses, including those associated with heart failure. 4 PKCs can be subdivided in three subgroups, according to their structure and enzymatic activity: 'conventional' PKCs (PKC a, b1, b2 and g), the enzymatic activity of which is calcium and phospholipid dependent; 'novel' PKCs (d, e, Z, y and m/PKD), the activity of which is calcium independent but phospholipid dependent; and 'atypical' PKCs (z, i/l and t), the activity of which is calcium and phospholipid independent. PKCa activation was found to precede the hypertrophy induced by the overexpression of the L-type voltage-dependent calcium channel in an animal model, 5 and its overexpression in cultured cardiomyocytes induces hypertrophy. 6 By contrast, the absence of PKCa prevents the transition from cardiac hypertrophy to failure. 7 PKCa is not the only PKC isoform involved in the maintenance of cardiac structure. Overexpression of PKCb1 also induces cardiac hypertrophy and sudden death in animal models, although its ablation does not abolish the hypertrophy induced by either pressure overload or infusion with hypertrophic agonists. 8, 9 PKCe is considered the most important isozyme protecting the heart from ischemia and reperfusion injury. Indeed, PKCe overexpression induces cardiac hypertrophy, but with preserved systolic function, suggesting an important role of PKCe for the development of 'compensatory' hypertrophy. 10 PKCy is known to have a crucial role in T-lymphocyte activation and to mediate various cellular responses in the skeletal muscle. [11] [12] [13] [14] [15] [16] [17] However, little is known about PKCy activity in cardiac function and remodeling. Calcineurin-induced hypertrophic signaling is associated with PKCa and PKCy activation, both in vivo and in vitro. 18 In addition, PKCy has been shown, along with the other members of the 'novel' PKCs subclass, to regulate localization of class II histone deacetylases (HDACs) in different cell systems. 15, 19 In the heart, HDACs act as inhibitors of cardiac hypertrophy, and PKCdependent nuclear export of HDAC5 is a critical event in the signaling cascade in cardiac hypertrophy. 19 We observed that PKCy is expressed at considerable levels in the cardiac muscle in mouse, and that it is rapidly activated after pressure overload, suggesting that it may have a role in cardiac response to environmental stimuli. We thus aimed to define the possible role of PKCy in cardiac structure and function.
Results
PKCh is expressed in cardiomyocytes, and it is rapidly activated after pressure overload. First, the expression of PKCy in cardiac muscle was analyzed by double immunofluorescence analysis: as shown in Figure 1A , PKCy expression is restricted to myosin heavy-chain (MyHC) þ cardiomyocytes. As expected, no PKCy immunoreactivity was detectable in the PKCy À/À hearts ( Figure 1A ). Moreover, western blot analysis showed that the lack of PKCy expression did not alter the expression levels of other PKC isoforms, such as PKCa or members of the novel class of PKCs, such as PKCd, PKCe and PKCZ ( Figure 1B) . To verify whether PKCy activity may be involved in cardiac remodeling, 10-to 16-week-old WT male mice were subjected to cardiac pressure overload through transverse aortic constriction (TAC). As control, a parallel group of mice was sham operated. After 15 min, the hearts were removed and total, soluble and particulate (membrane) protein fractions were prepared for western blot analysis. As shown in Figure 1C , PKCy rapidly translocated to the membrane fraction after TAC. Among the other isoforms analyzed, both PKCa and PKCe, the activation of which is known to be linked to cardiac hypertrophic response, also translocated to the membrane fraction, whereas no PKCd membrane translocation was observed, after 15 min of TAC. PKCy activation was also confirmed by western blot analysis using an antiThr538 p-PKCyspecific antibody: after TAC, a higher fraction of the total PKCy is phosphorylated (activated) as compared with sham-operated hearts ( Figure 1D ).
The lack of PKCh expression results in LV dysfunction.
To assess the effect of the lack of PKCy expression on cardiac structure and function, echocardiographic analyses were performed in 10-to 16-week-old male mice compared with age-and sex-matched WT mice (10 mice per genotype). LV diameters, wall thickness and contractile function were evaluated at basal conditions. LV from PKCy À/À mice displayed reduced wall thickness and enlarged diameter, when compared with WT mice (Table 1) . These findings are consistent with a pathological phenotype of dilated cardiomyopathy. As expected, a significant reduction in contractile performance was observed. Indeed, ablation of PKCy induced a 25-29% reduction in fractional shortening, associated with a parallel reduction in ejection fraction (Table 1 ). This defect in contractility was confirmed by the more accurate hemodynamic analysis of the pressurevolume curves (Table 2) , which showed that end-systolic volume was increased, whereas stroke volume and endsystolic elastance were decreased in PKCy À/À mice, when compared with WT mice.
The lack of PKCh expression induces cardiac fibrosis. To identify the LV characteristics that led to the observed cardiomyopathic phenotype, we performed histological analyses on the hearts of PKCy À/À and WT mice. Gomori's trichrome staining of 2-month-old PKCy À/À LV cryosections revealed a significant increase in interstitial fibrosis when compared with age-matched WT LVs (Figure 2A ). RT-PCR showed that the observed fibrosis was associated with an increase in the expression of collagens 1a1 and 3a1 (the main constituents of the cardiac extracellular matrix), as well as of a-SMA, a primary marker of fibroblast-to-myofibroblast conversion and TGFb, a fibrogenic growth factor ( Figure 2B ). Quantification of the fibrosis areas at different time points during postnatal life showed that in newborn mice, there was no significant increase in fibrosis in the LVs of either genotype; by contrast, a highly significant increase in the accumulation of interstitial fibrosis in PKCy À/À mice was observed with age, when compared with age-matched WT mice ( Figure 2C ).
To determine whether this increased fibrosis was due to the altered proliferation/activity of cardiac fibroblasts (CFs), cell proliferation was evaluated in vivo by 5-bromo-2 0 -deoxyuridine (BrdU) incorporation. Figure 3A shows that a significant increase in the percentage of BrdU þ ve cells was evident in 2-month-old PKCy À/À hearts, compared with WT hearts, and that BrdU þ ve cells were localized in interstitial, myosin
Àve areas, and can thus be regarded as CFs. The increased cell proliferation in PKCy À/À hearts was also confirmed by the increase in PCNA (a marker of the S phase) and Cyclin D1 (a marker of the G1/S phase transition) expression, as revealed by RT-PCR analysis ( Figure 3A ). To confirm that PKCy ablation leads to proliferation of CFs, these cells were also isolated from LVs of 1-to 3-day-old mice and their proliferation capability was analyzed in vitro. As shown in Figure 3B , a 60% increase in BrdU þ ve cells was observed in cultured PKCy À/À CFs, when compared with WT CFs. This increase was associated with a significant upregulation of Coll 1a1 expression.
The lack of PKCh expression induces hypertrophy of cardiomyocytes but reduces their number. Hematoxylin/ eosin staining of LV from 2-month-old mice also showed that the cardiac fibrosis we observed was associated with an increase in cardiomyocyte size ( Figure 4A ). The crosssectional area (CSA) of LV cardiomyocytes was evaluated by a-caveolin-3 (cardiomyocyte-specific) immunofluorescence, at different time points during postnatal life. As shown in Figure 4B , cardiomyocyte CSA was increased in PKCy PKCh and cardiomyocytes survival R Paoletti et al mice at all ages examined. Moreover, this increase in cardiomyocyte size was associated with a significant reduction in the number of cells at all ages examined. In fact, as shown in Figure 4B , y-ablation resulted in a reduction in the number of cardiomyocytes, ranging from 10%, at 1 month of age, up to 25% in subsequent growth phases, when compared with age-and sex-matched WT mice. Thus, we analyzed signaling proteins involved in cardiomyocyte death in response to hypertrophic and stress stimuli, namely p38 and JNK mitogen-activated protein (MAP) kinases. 20 We observed that p38 and JNK phosphorylations were both markedly higher in 2-month-old PKCy À/À LVs than in WT LVs. By contrast, phosphorylation levels of ERK1/2, which is implicated in cell proliferation/survival, were not altered ( Figure 4C ). Moreover, we analyzed the activation of a fetal gene expression program, which is usually associated with pathological LV remodeling. RT-PCR analysis showed that the expression of genes encoding atrial natriuretic factor (ANF), a-skeletal actin (a-SKA) and the fetal b-myosin heavy chain (b-MyHC), although barely detectable in LVs from 2-month-old WT mice, was high in LVs from age-and sexmatched PKCy À/À mice ( Figure 4D ). Moreover, in PKCy
LVs, the increased a-SKA mRNA level was associated with decreased a-cardiac actin (a-CAA) expression, when compared with WT LVs, where a-CAA isoform expression accounts for most of the actin expressed ( Figure 4D ). Interestingly, although the low level of a-SKA expression remained constant in LVs from WT mice, a progressive agerelated increase was observed in the a-SKA transcript level in PKCy À/À hearts (data not shown).
PKCh is required for cardiomyocyte survival. Next, we investigated whether the phenotype we observed was due to an impaired sensitivity to extracellular signals, to which heart cells are continuously exposed and which leads to cardiomyocyte death. Thus, we analyzed the adaptive response of cultured cardiomyocytes to such signals. Neonatal CMCs were isolated from 1-to 3-day-old PKCy À/À and WT mice. Morphological analysis showed that PKCy À/À CMCs were significantly larger (by B50%) than WT CMCs ( Figure 5A and B), reflecting the size increase observed in vivo. Moreover, actin filament organization resembled a hypertrophic phenotype, forming 'stress fiber-like structures', as shown by F-actin staining with phalloidin (data not shown). To examine the role of PKCy in the adaptive response of CMCs to work demand, CMCs were stimulated with phenylephrine (PE), the a1-adrenergic agonist. As expected, after 48 h of treatment, WT CMCs increased in size, reaching a size similar to that observed in untreated PKCy À/À CMCs. Accordingly, ANF expression was not detectable in untreated WT CMCs, whereas PE treatment induced evident perinuclear ANF protein accumulation. By contrast, upon agonist exposure, size was significantly reduced in PKCy À/À CMCs ( Figure 5A and B). Moreover, the perinuclear ANF protein accumulation, already evident in untreated PKCy À/À CMCs, was significantly reduced upon exposure to the agonist ( Figure 5A ). Similar results were obtained when CMCs were exposed to endothelin-1 or angiotensin II (data not shown).
To investigate the 'pathological' response to hypertrophic stimuli, the expression and activation of factors involved in the hypertrophic transduction pathways were analyzed in both WT and PKCy À/À CMCs, either treated with or without PE. As expected, when WT CMCs were treated with PE for 30 min, a significant 30% increase in Akt phosphorylation was observed by western blot analysis as a result of the hypertrophic response. By contrast, no increase in Akt phosphorylation was observed in PKCy À/À CMCs upon PE treatment. (Figure 5B ).
When WT CMCs were treated with PE for longer periods of time (48 h), an increase in both the ANF and MyHC expression levels was observed, as expected. By contrast, the higher basal expression level of both ANF and MyHC in PKCy were observed in WT CMCs, regardless of whether they were exposed to PE. Degradation and/or release of regulatory myofibrillar proteins, such as cd-TnI or cd-TnT, are known to occur upon cardiomyocyte damage. 21 Trypan blue and TUNEL analyses were then used to investigate whether treatments induced cell death in PKCy À/À CMCs ( Figure 5C ). At basal conditions in serum-free medium, the percentage of PKCy À/À CMCs permeable to trypan blue was already 2.5 times higher than in WT cells. PE exposure (48 h) resulted in a further increase in the percentage of trypan blue-positive CMCs, when compared with untreated PKCy À/À CMCs. No differences were observed in WT cells upon treatment. Similar results were obtained when CMCs were exposed to endothelin-1 or angiotensin II, as well as to environmental stress stimuli, such as hypoxic conditions (data not shown). To verify whether the observed cell death was due to protease activity, CMCs were treated with leupeptin (Leu), a protease inhibitor preferentially active on calpains, before being exposed to PE. A 30-min Leu pretreatment, followed by 48 h of exposure to PE, significantly reduced trypan bluepositive PKCy À/À CMCs to a level comparable with WT CMCs ( Figure 5C ).
TUNEL analysis was performed to assess whether the cell death we observed was due to apoptosis. At basal conditions in serum-free medium, the percentage of TUNEL-positive nuclei was already higher in PKCy À/À than in WT cells ( Figure 5D ). PE exposure (48 h) induced, in PKCy À/À CMCs, a further increase (about three times) in the percentage of apoptotic nuclei, if compared with unstimulated cells. By contrast, no increase was detectable in PE-treated WT CMCs ( Figure 5D ). Similar results were obtained using endothelin-1 and angiotensin II treatments (data not shown).
To characterize which apoptotic pathway is active in the absence of PKCy, PKCy À/À and WT CMCs were treated with or without PE for 4 h; cleavage of caspase-9 and caspase-8 was analyzed by western blot. As shown in Figure 5E , the caspase-9 proteolitic fragment (p35/36, the active form) was evident in untreated PKCy À/À CMCs, and it was further accumulated after 4 h PE treatment. Very little, if no, caspase-9 cleavage was observed in WT CMCs, and PE exposure induced a slight increase in p35/36 accumulation. By contrast, no cleaved/active fragments of caspase-8 were detectable in both WT and PKCy À/À CMCs, although a slight increase in full-length caspase-8 accumulation was evident after 4 h PE, in both WT and PKCy À/À CMCs to a similar extent.
Discussion
In this paper, we show that the expression/activity of the y-isoform of PKCs ensures the correct structure and function of cardiac muscle, at least in part, by protecting cardiomyocytes from cell death. As first, PKCy is expressed at a considerable level in mouse cardiomyocytes; moreover, it is strongly activated, together with PKCa and PKCe, within 15 min of aortic banding, suggesting that it may have a pivotal role in the cardiac response to pressure overload. Both PKCa and PKCe have been implicated in cardiac hypertrophy, based on in vivo and in vitro studies, although they probably have different roles. 4 In particular, PKCa is supposed to be involved in the transition from hypertrophy to heart failure, whereas PKCe is believed to be involved in compensatory hypertrophy. 7, 22 The fact that both isoforms are rapidly (within 15 min) activated upon pressure overload, which has never been investigated before, indicates that the actual outcome of the stimulus (maladaptive or compensatory hypertrophy) depends on a delicate balance between the different pathways. Interestingly, PKCd, the activity of which has been proposed to be somehow redundant to PKCe activity with respect to cardiac hypertrophy, 22 does not change. This observation suggests that, unlike PKCe, PKCd is not involved in the early response to pressure overload and does not behave exactly as PKCe. Moreover, PKCd is structurally related to PKCy, which behaves similarly to PKCe to pressure overload, instead. Whether PKCy and PKCe, which belong to the same PKC subfamily as PKCd, may have similar or specific roles in the response of heart to pressure overload will need further investigation.
However, the data reported in this paper show that the lack of PKCy expression in vivo results in basal cardiac dysfunction, differently from what occurs in the absence of PKCe, 23 highlighting a possible distinguished and specific role for PKCy in cardiac structure and function under physiological conditions. Indeed, PKCy À/À mice exhibit abnormalities in several contractility indexes. In particular, the lack of PKCy expression affects the ejection phase of the LV systole, although it does not have any effect on the diastole or on the isovolumic phase of systole. On this issue, indexes of the ejection phase have been identified as the most reliable parameter for detecting depressed myocardial function. 24 This loss of cardiac function is associated with a structural defect, consisting of reduced wall thickness and greater LV diameter. The combination of dilation and thinner muscle wall reduces the efficiency of heart performance, which results in lower contractile power per cardiac area. It is noteworthy that in most of the animal models, lacking or overexpressing specific PKC isoforms, altered cardiac function is only evident in response to pathological stimuli. 4, 23, 25 Even ablation of PKCe, which is considered the most important isozyme protecting the heart from ischemia and reperfusion injury, did not exert any basal cardiac phenotype, although the combination of loss-and gain-of-function approaches, aimed to modulate its translocation, suggested a role for PKCe signaling in normal postnatal maturational myocardial development, probably regulating cardiomyocytes proliferation. 22, 23 This fact suggests that most PKC isoforms are modifiers of heart response to specific stimuli, or that the eventual redundancy between them can preserve basal physiology in mutant models. By contrast, the absence of PKCy affects the normal physiology of the heart. Thus, PKCy, differently from any other isoform, may be considered a key protein for cardiac structure and function under physiological conditions. Moreover, the cardiomyopathy observed in PKCy À/À mice is associated with a profound alteration in the cellular and extracellular structure of the heart. Indeed, increased interstitial fibrosis was observed in the absence of PKCy. This increase occurs during postnatal heart growth, as demonstrated by the fact that no differences were observed in the hearts of newborn mice and that fibrotic areas increased with age. This is the result of increased myofibroblast proliferation and matrix deposition, as shown by both in vivo and in vitro analyses, possibly as a consequence of the progressive loss of cardiomyocytes observed in the hearts lacking PKCy. As a result, the surviving cardiomyocytes À/À mice. The representative experiment is shown. Relative fold inductions are shown, as determined by densitometric analyses of western blots from three independent experiments (n ¼ 9 per genotype), using a-tubulin expression for normalization (**Po0.001 versus WT). (D) RT-PCR analysis of the expression of ANF (atrium natriuretic factor), a-SKA (a-skeletal actin), a-CAA (a-cardiac actin), b-MyHC (b-myosin heavy chain) in 2-month-old WT and PKCy À/À LVs. GAPDH expression was used to normalize the reaction undergo stress response, as shown by the progressive increase in cell size, as well as by the upregulation of the expression of fetal genes, such as ANF, a-SKA and b-myosin. Indeed, the return to a pattern of fetal metabolism is considered a common feature of a hemodynamically or metabolically stressed heart. 26 Taken together, these data suggest that ablation of PKCy results in cardiomyocyte loss, which, in turn, promotes cardiac remodeling, fibrosis and ventricular dilation; this indicates that PKCy is required for cardiomyocyte survival, as it has previously been shown for other cell types. 11, 12 Indeed, whereas no alterations were observed in prosurvival (ERKs) activities, an increase in proapoptotic (p38 and JNK) activities was observed in LVs lacking PKCy. Interestingly, PKCe and PKCd are known to activate MAP kinase signaling pathways in cardiomyocytes, 27 and the diastolic dysfunction and interstitial fibrosis observed in PKCe À/À mice after pressure overload, are associated with a decrease in ERK and an increase in p38 and JNK phosphorylations, as the latter is probably dependent on PKCd upregulation. 25 As no alteration in PKCe or PKCd expression was observed PKCy À/À hearts, the results obtained in our study suggest that PKCy activity is required to maintain the correct balance between MAPK pathways and, consequently, to ensure physiological cell survival. Several mouse models now show that cardiomyocyte death itself may directly cause dilated cardiomyopathy. 28 Although no supporting data are available yet, it is possible that PKCy activity is required on one hand to counterbalance the PKCd-dependent activation of p38 and JNK, whereas, on the other hand, to support the survival of PKCe-induced proliferating cardiomyocytes. Intriguingly, the phenotype observed in PKCe À/À mice after pressure overload, wherein PKCd is upregulated, presents many similarities to those observed in basal condition when PKCy is ablated. 25 In keeping with in vivo observations, cultured CMCs lacking PKCy acquire a hypertrophic-like phenotype, as shown by both morphological and molecular analyses; in fact, increased accumulation of both ANF and MyHC is evident in PKCy À/À CMCs, although Akt expression and phosphorylation are not affected, suggesting that the phenotype observed is Akt independent. Surprisingly, the lack of PKCy prevents pharmacologically induced hypertrophy; rather, cell size decreases, and the expression of ANF and MyHC, and Akt activation is prevented. Indeed, PKCy À/À CMCs are more susceptible to cell death than WT CMCs, both at basal condition and after pharmacological or environmental stressinduced stimuli. The fact that the death of PKCy À/À CMCs can be prevented by treatment with leupeptin, a protease inhibitor, shows that the observed cell death can be attributed to protease activities. It is noteworthy that leupeptin preferentially inhibits calpain activity, thereby highlighting a possible role of this class of proteases in the cell death observed in our study. Indeed, reduced expression of the regulatory myofibrillar protein cd-TnI was observed in PKCy À/À . Troponins are susceptible to proteolytic degradation by intracellular proteases, such as calpain-I, caspases and matrix metalloproteinase-2, which occur in reversibly or irreversibly damaged cardiomyocytes. 29, 30 As a consequence, degradation products of troponins are detected in the serum of patients with acute myocardial infarction, and it is considered as a reliable clinical cardiovascular biomarker. 31 Accordingly, TUNEL analysis shows that the observed cardiomyocyte death is mainly due to apoptosis, and, in particular, activation of the intrinsic cell death pathway, as caspase-9, but not caspase-8, cleavage was observed in PKCy À/À CMCs, and was further increased after PE exposure. The involvement of PKCy in this pathway is supported by a number of observations in T cells wherein it is well documented that PKCy promotes cell survival by both inhibiting the proapoptotic factor Bad and activating the antiapoptotic factor Bcl xL . 11, 12 Further experiments are warranted to more accurately define the molecular mechanisms underlying the observed phenotype and the relative contribution of the PKCy-regulated signaling pathways. PKCy, as a member of the nPKCs subfamily, is known to mediate the nuclear export of class II HDACs, probably by regulating PKCm/PKD activity. 15, 19 Class II HDACs act as negative regulators of pathological cardiac remodeling through their association with the myocyte enhancer factor-2 transcription factor and other prohypertrophic transcriptional regulators. 32 However, recent data, based on a PKD1 conditional knock out, suggest that PKD1 is required to actually transduce stress stimuli involved in pathological cardiac remodeling in vivo. 33 As PKD1 is a common substrate for all members of the novel class of PKCs, it is conceivable that PKCy may also have a specific role in the regulation of heart maintenance, besides exerting its activity on PKD functions.
In conclusion, the results reported in this paper show that PKCy ensures cardiac muscle homeostasis, at least in part, by preventing cardiomyocyte cell death in response to work demand and neuro-hormonal signals, to which heart cells are continuously exposed. This study advances the understanding of cellular mechanisms responsible for preservation of myocardial integrity, and the observation that PKCy can be considered a key protein for cardiac structure and function under physiological conditions, may thus be instrumental for future development of therapeutic strategies for the treatment of pathological cardiac remodeling and heart failure, using select PKCy isoform modulators.
Materials and Methods Animals. PKCy À/À mice (C57BL/6J background strain) were kindly provided by Littmann and colleagues. 34 For in vivo studies, 2-month-old male mice were used throughout the experiments, unless otherwise specified. The animals were housed in the Histology Department accredited animal facility. All the procedures were approved by the Italian Ministry for Health and conducted according to the US National Institutes of Health guidelines.
Antibodies. The following primary antibodies were used: the antimyosin heavychain MF20, 35 the anti-ANF (Bachem, Bubendorf, Switzerland); the anti-caveolin-3, the anti-PKC-a, -d, -e, -Z, -y and the anti-phospho Thr538 PKCy (BD Bioscience, Franklin Lake, NJ, USA); the anti-Akt, the anti-phosphoAkt, the anti-phosphoGSK3b and the anti phospho-p38 (Cell Signalling Inc., Danvers, MA, USA); the anti-caspase-9 (Assay Designs, Ann Arbor, MI, USA); the anti-caspase-8 (Santa Cruz Biotec, Santa Cruz, CA, USA); the anti-a-tubulin (Sigma-Aldrich, St. Louis, MO, USA).
Transthoracic echocardiography. Echocardiographic analysis was performed using a high-resolution echocardiograph (VeVo 770, Visualsonics, Toronto, ON, Canada) equipped with a 33 MHz transducer. End-diastolic and end-systolic intraventricular septum (IVSTd, IVSTs), posterior wall thickness (PWTd, PWTs) and LV internal diameters (LVEDD, LVESD) were measured. Percentage fractional shortening (%FS) and relative ejection fraction (EF) were calculated using standard formulas:
%FS ¼ ½ðLVEDD À LVESDÞ=LVEDDÂ100 EF ¼ ½ðLV End À diastolic volume À LV End À systolic volumeÞ= LV End À diastolic volumeÂ100 LV hemodynamics. Mice were anesthetized with an intraperitoneal injection of ketamine/xylazine (80/10 mg/kg body weight), and inotropic and lusitropic functions were evaluated by measuring intraventricular volume and pressure using a micromanometer catheter (Millar 1.4 F, SPR 671, Millar Instruments, Houston, TX, USA) positioned in the LV through right common carotid artery cannulation. 36 An estimate of systolic and diastolic LV performance was yielded by a series of pressure-volume loops of consecutive cardiac cycles.
Thoracic aortic constriction. Thoracic Aortic Constriction (TAC) was imposed between the truncus anonymous and the left carotid artery using a 7-0 nylon suture ligature, as described previously. 36 A separate group of mice underwent the same surgical procedures, but without aortic stenosis (sham operated). Fifteen minutes after TAC, simultaneous left and right carotid pressures were measured under anesthesia, to assess the degree of pressure load. Immediately after, the hearts were removed, the chambers dissected, weighed and processed for protein extraction.
